China’s Theranostics Market, estimated at US$ XX billion in 2024 and 2025, is projected to grow steadily at a CAGR of XX% from 2025 to 2030, ultimately reaching US$ XX billion by 2030.
The global theranostics market was valued at $1.9 billion in 2022, increasing to $2.1 billion in 2023, and is projected to reach $4.3 billion by 2028, with a robust compound annual growth rate (CAGR) of 15.5%.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=111696976
Drivers
The China Theranostics Market is experiencing substantial growth driven by several powerful factors, primarily the escalating incidence of cancer, which creates a critical demand for highly effective, personalized treatment and diagnostic solutions. Theranostics, which combines targeted diagnostics (like PET/CT imaging) with targeted therapy (like Radionuclide Therapy), is uniquely positioned to address this need by offering precise disease localization and tailored treatment delivery, minimizing damage to healthy tissues. Significant governmental support is also a key catalyst, evidenced by initiatives such as the “Mid- and Long-Term Development Plan for Medical Isotopes (2021–2035),” which aims to expand advances in nuclear medicine and theranostics infrastructure across the country. Furthermore, the rising adoption and clinical exploration of specific theranostic pairs, such as Ga-DOTATATE and 177Lu-DOTATATE for neuroendocrine tumors and targeted therapies for prostate cancer (like 68Ga-PSMA PET/CT and 177Lu-PSMA-617 therapy), highlight the increasing confidence and investment in this field. The growing focus on biomarker screening and molecular imaging techniques, coupled with the rising trend of modernizing imaging workflow systems in hospitals and cancer care centers, further propels the market. China’s large patient base and government efforts to decentralize and modernize cancer care create a fertile environment for the domestic adoption and development of innovative theranostic solutions, thereby acting as a powerful market driver.
Restraints
Despite the promising growth trajectory, the China Theranostics Market faces several significant restraints that challenge its broader adoption and commercialization. A primary constraint is the complex and highly regulated environment surrounding the production and supply chain of medical radioisotopes and radiopharmaceuticals. Disruptions in the availability of key radioisotopes, such as Lutetium-177 or Gallium-68, can severely limit the capacity for both diagnostic imaging and therapeutic procedures. Furthermore, the high initial capital investment required for specialized infrastructure, including hot labs, high-end diagnostic imaging equipment (like PET/CT scanners), and dedicated theranostics centers, poses a significant financial barrier, particularly for healthcare facilities in lower-tier cities. Another major restraint is the shortage of trained nuclear medicine specialists, radiochemists, and technical personnel competent in handling, preparing, and administering radiopharmaceuticals. The long-term safety and efficacy data for some novel theranostic agents are still evolving, leading to cautious adoption among some clinicians and requiring more extensive clinical validation to secure widespread market trust and regulatory acceptance. These challenges related to isotope supply, high costs, infrastructure requirements, and workforce expertise collectively slow the market’s expansion and restrict the availability of advanced theranostic options across the vast Chinese healthcare system.
Opportunities
The China Theranostics Market is rich with opportunities, particularly through the expansion of targeted therapies for highly prevalent cancers and the development of localized domestic manufacturing capabilities. A major opportunity lies in leveraging China’s considerable investment in life sciences R&D to develop novel proprietary theranostic agents beyond the currently prominent prostate and neuroendocrine tumor applications, especially targeting prevalent cancers like lung and gastric cancer. The rising trend of modernizing clinical pathways and the growing focus on personalized medicine initiatives are creating an accelerated demand for integrated diagnostic and therapeutic solutions, directly matching the core offering of theranostics. Emerging opportunities exist in the commercialization of domestic advanced equipment and the establishment of dedicated theranostics centers, moving away from reliance on imported technologies. Furthermore, the integration of Artificial Intelligence (AI) and software solutions presents a substantial growth opportunity by enhancing the efficiency of image analysis, optimizing treatment planning, and managing patient data from diagnostic scans to therapeutic outcomes. The vast, underserved patient population in emerging regional centers presents an untapped market where expanded government funding and policy support for nuclear medicine can accelerate the deployment of theranostic platforms, offering substantial revenue potential for both international companies and domestic manufacturers specializing in radiopharmaceuticals and IVD/biomarker screening.
Challenges
Several critical challenges must be navigated for the China Theranostics Market to achieve its full potential. The inherent complexity in developing and consistently producing high-quality radiopharmaceuticals presents a continuous hurdle, requiring strict adherence to Good Manufacturing Practice (GMP) standards, which can be challenging to maintain at scale across multiple sites. Regulatory harmonization and efficient approval processes for new theranostic drug-device combinations remain a persistent challenge, as these integrated products often require parallel approval pathways for both the diagnostic component and the therapeutic agent. Furthermore, ensuring equitable access and affordability across the diverse economic landscape of China is difficult, as the high cost of theranostic procedures can limit their coverage under national insurance schemes, creating disparities between urban and rural access. Technical challenges, such as the need for robust quality control of imaging and therapeutic doses, and ensuring adequate radiation safety protocols in clinical settings, demand continuous monitoring and investment. Finally, market fragmentation and the absence of standardized clinical guidelines for the use of many theranostic pairs complicate national adoption and limit the ability to conduct large-scale, unified clinical trials necessary for widespread evidence-based practice. Overcoming these economic, regulatory, and logistical complexities is crucial for market penetration.
Role of AI
Artificial Intelligence (AI) is set to be a pivotal and transformative force in the China Theranostics Market, primarily by optimizing and streamlining the complex clinical workflow inherent in theranostic practice. AI algorithms can significantly enhance the precision of diagnostic imaging, such as PET/CT scans, by improving image segmentation, reducing noise, and providing automated quantitative analysis of tumor uptake, leading to more accurate disease staging and response assessment. In the therapeutic phase, AI plays a crucial role in dosimetry and treatment planning, allowing for personalized calculation of the optimal therapeutic dose of the radiopharmaceutical (e.g., 177Lu) based on the patient’s individual bio-distribution data, thereby maximizing tumor kill while minimizing damage to critical organs. Furthermore, AI can accelerate the drug discovery process for new theranostic agents by analyzing vast datasets of patient genomics and imaging characteristics to identify novel biomarkers and predict patient responsiveness to treatment. The implementation of AI-powered software platforms will also be critical for managing the high volume of complex data generated throughout the theranostic journey, from initial biomarker screening to long-term follow-up, ensuring faster turnaround times and supporting better clinical decision-making across China’s expanding network of theranostics centers.
Latest Trends
The China Theranostics Market is currently shaped by several dynamic trends reflecting advancements in nuclear medicine and oncology. One major trend is the deepening focus on personalized treatment strategies, where theranostics is transitioning from a niche treatment to a mainstream oncology tool for select patient populations, driven by strong clinical data, particularly in prostate cancer (PSMA targeting) and neuroendocrine tumors (DOTATATE targeting). The convergence of diagnostic imaging with targeted radiopharmaceuticals is accelerating the development of new pairings for various solid tumors beyond the established applications, including FAP (Fibroblast Activation Protein) targeting for broader cancer types. Another key trend is the increasing vertical integration within the domestic market, where Chinese companies are investing heavily in establishing their own local capabilities for the production of medical radioisotopes and advanced radiopharmaceuticals to ensure a stable supply chain and reduce reliance on international imports. Furthermore, there is a strong shift towards the use of advanced digital solutions, including AI-driven software for complex image analysis and treatment dosimetry, which is becoming essential for maintaining the high quality and efficiency of theranostic procedures. Finally, the rapid construction and modernization of nuclear medicine and theranostics centers in major metropolitan areas reflect an institutional commitment to adopting these cutting-edge therapies, positioning China as a key leader in the global theranostics landscape.